WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards’ latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower rates of paravalvular leak (PVL) at 30 days, lower echo-derived gradients and larger effective orifi ...

Edwards Lifesciences (EW) has been gaining from strength across all key segments. Innovation also aids growth. The stock carries a Zacks Rank #2 (Buy) currently.Edwards’ Surgical Structural Heart business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. The RESILIA portfolio has been widely adopted because of the excellent durability of its proven tissue technology. The company is optimistic about the future of this technology as i ...

Investors interested in Medical - Instruments stocks are likely familiar with Hologic (HOLX) and Edwards Lifesciences (EW) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate ...

Edwards Lifesciences Corporation (EW) is gaining from its commitment to advance its leadership position in surgical structural heart therapies. The SAPIEN 3 Ultra RESILIA platform also continues its strong uptake in the United States.Elevated expenses and foreign exchange headwinds are a concern for EW’s business.In the past year, this Zacks Rank #2 (Buy) stock has gained 13.4% compared with 11.2% rise of the industry and 30.8% growth of the S&P 500 composite.The renowned global medical device company has a ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. About Edward ...

Edwards Lifesciences (EW) is benefiting from strength across all product groups. The company’s bullish long-term growth strategy buoys optimism on the stock. The stock currently carries a Zacks Rank #2 (Buy).In December 2023, Edwards announced the strategic decision to spin off the Critical Care segment at the end of 2024. The company expects this tax-free, planned separation to act strategically to its core business. With this spin-off, the company pursues more opportunities for Transcatheter Aortic Valve ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File Number 1-15525 EDWARDS LIFESCIENCES CORPORATION (Exact name of registrant as specified in its charter) Delaware 36-4316614 (St ...

Edwards Lifesciences Corporation (EW) reported adjusted earnings per share (EPS) of 64 cents in fourth-quarter 2023, in line with the Zacks Consensus Estimate. The figure is also in line with the year-ago quarter’s level.The quarter’s one-time adjustments primarily include the spin-off of Critical care and the prior period’s ongoing tax.GAAP EPS were 61 cents in the quarter, down 6.2% year over year.For the full year, adjusted earnings were $2.30 per share, down 5.7% from the year-ago period’s levels. It al ...

Edwards Lifesciences Corporation (NYSE:EW) Q4 2023 Earnings Conference Call February 6, 2024 5:00 PM ET Company Participants Mark Wilterding - Investor Relations and Treasurer Bernard Zovighian - Chief Executive Officer Scott Ullem - Chief Financial Officer Daveen Chopra - Global Leader of TMTT Larry Wood - Group President of TAVR and Surgical Structural Heart Wayne Markowitz - Global Leader of Surgical Structural Heart Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Trav ...

For the quarter ended December 2023, Edwards Lifesciences (EW) reported revenue of $1.53 billion, up 13.8% over the same period last year. EPS came in at $0.64, compared to $0.64 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.5 billion, representing a surprise of +2.27%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.64.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...